Tanioka H, Shimada K, Tsuji A, Kochi M, et al. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. Anticancer Res 2022;42:2675-2681.
PMID: 35489740